0000000000272102

AUTHOR

Daniel Dusser

showing 3 related works from this author

New horizons in early stage COPD--improving knowledge, detection and treatment.

2011

SummaryEarly stage COPD carries a significant healthcare burden that is currently underrecognised, underdiagnosed and undertreated. Furthermore, patients at this stage can rapidly decline to advanced disease, especially if they continue to smoke. The natural history of the disease in early stages remains largely unknown, and emerging evidence indicates that we are able to reduce lung function decline and exacerbations, and improve quality of life, in early stage COPD, mainly through smoking cessation. But new evidence from randomised clinical trials also suggests an impact of pharmacotherapy on clinical outcomes in early disease. Guidelines need to be updated to reflect this greater underst…

Pulmonary and Respiratory MedicineMalemedicine.medical_specialtyHealth Knowledge Attitudes Practicemedicine.medical_treatmentDiseasePulmonary Disease Chronic ObstructiveQuality of life (healthcare)PharmacotherapyHealth careDiagnosismedicineCOPDHumansIntensive care medicineCOPDbusiness.industryCase-findingEarly diseasemedicine.diseasePrognosisBronchodilator AgentsClinical trialNatural historyTreatmentEarly DiagnosisSpirometryPractice Guidelines as TopicPhysical therapyQuality of LifeSmoking cessationFemaleSmoking CessationbusinessRespiratory medicine
researchProduct

Non-classic cystic fibrosis associated with D1152HCFTR mutation

2010

Burgel P-R, Fajac I, Hubert D, Grenet D, Stremler N, Roussey M, Siret D, Languepin J, Mely L, Fanton A, Labbe A, Domblides P, Vic P, Dagorne M, Reynaud-Gaubert M, Counil F, Varaigne F, Bienvenu T, Bellis G, Dusser D. Non-classic cystic fibrosis associated with D1152H CFTR mutation. Background: Limited knowledge exists on phenotypes associated with the D1152H cystic fibrosis transmembrane conductance regulator (CFTR) mutation. Methods: Subjects with a D1152H allele in trans with another CFTR mutation were identified using the French Cystic Fibrosis Registry. Phenotypic characteristics were compared with those of pancreatic insufficient (PI) and pancreatic sufficient (PS) cystic fibrosis (CF)…

AdultMalemedicine.medical_specialtyConsensusPancreatic diseaseAdolescentCystic FibrosisGENETICSmedicine.medical_treatmentCystic Fibrosis Transmembrane Conductance RegulatorCystic fibrosisGastroenterologyMembrane PotentialsCohort StudiesYoung AdultChloridesInterquartile rangeForced Expiratory VolumeInternal medicineCYSTIC_FIBROSISHumansMedicineLung transplantationGenetic Predisposition to DiseaseChildSweatExocrine pancreatic insufficiencyMUTATIONGenetics (clinical)AgedBronchiectasisbiologybusiness.industryHomozygoteMiddle Agedmedicine.diseaseCongenital absence of the vas deferensCystic fibrosis transmembrane conductance regulatorNasal MucosaEndocrinologyAmino Acid SubstitutionChild Preschoolbiology.proteinFemalebusiness
researchProduct

P149 Once-daily tiotropium Respimat® add-on to at least ICS in adult patients with symptomatic asthma: pooled safety analysis: Abstract P149 Table 1

2015

Background A high proportion of patients with asthma are symptomatic despite at least ICS maintenance therapy. Five trials aimed to evaluate the safety of tiotropium Respimat® compared with placebo Respimat®, each as add-on to at least ICS in adult patients with symptomatic asthma. Methods Five Phase III and one Phase II randomised, double-blind, placebo-controlled, parallel-group trials. PrimoTinA-asthma® (48 weeks): tiotropium Respimat® 5 µg add-on to ICS + LABA (≥800 µg budesonide or equivalent); MezzoTinA-asthma® (24 weeks): tiotropium Respimat® 5 µg or 2.5 µg add-on to ICS (400–800 µg budesonide or equivalent); GraziaTinA-asthma® (12 weeks): tiotropium Respimat® 5 µg or 2.5 µg add-on t…

Pulmonary and Respiratory MedicineBudesonideRespimatAdult patientsbusiness.industrymedicine.diseasePlacebohumanitiesrespiratory tract diseasesSafety profileMaintenance therapyAnesthesiamedicineOnce dailybusinesshuman activitiesmedicine.drugAsthmaThorax
researchProduct